DAIICHI SANKYO, INC.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 50
- Registration Number
- NCT06174987
- Locations
- 🇺🇸
Miami Cancer Institute, Miami, Florida, United States
🇺🇸Duke University - Trent Center, Durham, North Carolina, United States
🇦🇺Flinders Medical Center, Bedford Park, Australia
Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- Drug: HER3-DXd
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- Daiichi Sankyo Inc.
- Target Recruit Count
- 154
- Registration Number
- 2023-507641-29-00
- Locations
- 🇧🇪
UZ Brussel, Jette, Belgium
🇧🇪Antwerp University Hospital, Edegem, Belgium
🇫🇷Assistance Publique Hopitaux De Marseille, Marseille, France
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Solid Cancer
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 650
- Registration Number
- NCT06161025
- Locations
- 🇺🇸
'Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Perlmutter Cancer Center at NYU Langone Hospital- Long Island, Mineola, New York, United States
🇺🇸NYU Langone Health, New York, New York, United States
Medical Access Program for Patritumab Deruxtecan
- Conditions
- Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT06099639
- Locations
- 🇺🇸
Highlands Oncology, Springdale, Arkansas, United States
🇺🇸Southern California Permanente Medical Group, Los Angeles, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
- Conditions
- Hormone-receptor-positive Breast CancerHER2-low Breast CancerHER2-negative Breast Cancer
- Interventions
- Other: No drug
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 927
- Registration Number
- NCT06040593
- Locations
- 🇺🇸
ConcertAI database, Cambridge, Massachusetts, United States
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 12
- Registration Number
- NCT05979831
- Locations
- 🇫🇷
Saint Louis Hospital, Paris, France
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 250
- Registration Number
- NCT05950945
- Locations
- 🇺🇸
Mount Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸USF College of Medicine, Tampa, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 470
- Registration Number
- NCT05875168
- Locations
- 🇨🇦
McGill University Health Center, Montreal, Canada
🇨🇦Princess Margaret Cancer Center, Toronto, Canada
🇨🇳Shanghai East Hospital, Shanghai, China
A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1100
- Registration Number
- NCT05804747
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer
- Conditions
- HER2-positive Breast Cancer
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 865
- Registration Number
- NCT05769751
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Affiliated Cancer Hospital of Shandong First Medical University, Jinan, China